Alex Goldberg

Galena Biopharma, Inc. (NASDAQ:GALE) and Melco Crown Entertainment Limited (NASDAQ:MPEL) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 12/27/2013 -- -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Galena Biopharma, Inc. (NASDAQ:GALE) and Melco Crown Entertainment Limited (NASDAQ:MPEL).

Galena Biopharma, Inc. (NASDAQ:GALE) a biopharmaceutical company that focuses on developing oncology treatments to address major unmet medical needs to advance cancer care closed up in its previous session (+1.75%) on 1,549,911 shares traded. Galena Biopharma, Inc. (NASDAQ:GALE) is currently up (+175%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Galena Biopharma, Inc. (NASDAQ:GALE)

Melco Crown Entertainment Limited (NASDAQ:MPEL) a company that through its subsidiaries, develops, owns, and operates casino gaming and entertainment resort facilities in Macau closed up in its previous session (+1.56%) on 1,532,984 shares traded. Melco Crown Entertainment Limited (NASDAQ:MPEL) is currently up (+142.6%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Melco Crown Entertainment Limited (NASDAQ:MPEL)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com